Institute for Integrative Therapies

What Institute for Integrative Therapies does

Institute for Integrative Therapies (IIT) is a private, Eden Prairie, Minnesota-based psychedelic medicine clinic founded in 2019 by Dr. Manoj Doss, DO, and recognized as Minnesota's first psychedelic medicine clinic. The clinic delivers ketamine-assisted psychotherapy (KAP) via intramuscular injection, intravenous ketamine infusions for mental health and chronic pain, FDA-approved Spravato (esketamine) for treatment-resistant depression, and adjunctive wellness services including IV vitamin infusions, NAD+ longevity therapy, peptide therapy, and wellness coaching. Patient care follows a proprietary bio-psycho-spiritual framework that combines physician-led medical management with structured preparation and integration therapy across physiologic, psychological, and spiritual domains.

The organization operates as a hybrid clinical practice and clinical research site, with GCP-compliant infrastructure supporting Phase 2 and Phase 3 psychedelic trials in partnership with COMPASS Pathways (COMP360 psilocybin), atai/Beckley (VLS-01 DMT), and Cybin (psilocin EMBRACE/EXTEND studies). GTM is sales-led direct-to-consumer via phone, website contact, and community events, with in-network insurance relationships (BCBS, Cigna, Aetna, UCare, HealthPartners, Medica, Tricare, Allina) covering Spravato and physician services, while KAP and IV ketamine are predominantly self-pay ($500-$850 per session). Pricing follows a fee-for-service model with bundle options for multi-session courses.

Revenue is diversified across fee-for-service clinical care, insurance-billed Spravato and physician visits, clinical trial site fees from biotech sponsors, and cash-pay wellness add-ons. The clinic has trained more than 50 clinicians through an internal apprenticeship program and hosts graduate research interns from UW-Madison's Psychoactive Pharmaceutical Investigation Master's Program. At-home sublingual ketamine therapy is offered through a partnership with Nue Life, and group KAP retreats expand the channel beyond individual in-clinic visits. Headcount is reported at 11-50 employees, consistent with a specialized regional clinical operation.

Name

Institute for Integrative Therapies

Legal name

Institute for Integrative Therapies

Website

https://iit-mn.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Institute for Integrative Therapies is a Minnesota-based psychedelic medicine clinic offering ketamine-assisted psychotherapy, IV ketamine infusions, Spravato, and wellness services for patients with treatment-resistant mental health and chronic pain conditions, while also serving as a Phase 2/3 clinical trial site for leading psychedelic biotechnology sponsors.

Ownership category

akta.pro rank

Product category

Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Outpatient Mental Health & Counseling Clinics (HLAFABAC)

akta.pro secondary industries

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA), Psychiatry & Medication Management (EDALAFAC)

Keywords

• Ketamine-assisted psychotherapy
• Psychedelic medicine clinic
• Mental health treatment
• Clinical research trials
• Integrative therapy services

Headquarters

HQ city

Eden Prairie

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Ketamine-Assisted Psychotherapy (KAP): Fee-for-service model for intramuscular ketamine sessions with therapist present. Self-pay pricing of $850 per session. Includes preparation and integration sessions. Insurance may cover physician and office time.
2. Ketamine Infusions: IV ketamine infusions for mental health ($500 per 1-hour session) and chronic pain ($850 per 2-hour session). Insurance-covered pricing available for in-network plans. Bundle options available for private pay.
3. Spravato (Esketamine): FDA-approved nasal spray for treatment-resistant depression, typically covered by most insurance plans. Induction phase includes two treatments per week for four weeks.
4. Wellness Services: IV wellness infusions (Myers Mix, Immunity Boost, Revitalize at $225 each), longevity medicine, peptide therapy, and wellness coaching. Added to ketamine infusions for $150.
5. Clinical Research: Participation in industry-sponsored clinical trials evaluating novel psychedelic treatments. Revenue derived from clinical trial site agreements with pharmaceutical partners including COMPASS Pathways, ataiBeckley, and Cybin.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Institute for Integrative Therapies is a psychedelic medicine clinic that administers ketamine-based treatments (intramuscular ketamine-assisted psychotherapy, IV ketamine infusions for mental health and chronic pain, and FDA-approved esketamine/SPRAVATO) to individuals with treatment-resistant mental health conditions. Services are paired with structured preparation and integration psychotherapy under a bio-psycho-spiritual model, supplemented by wellness IV infusions, longevity and peptide therapy, and clinical research site services for Phase 2/3 psilocybin, DMT, and psilocin trials sponsored by biotech partners.

Product overview

Institute for Integrative Therapies operates as a psychedelic medicine clinic offering a comprehensive suite of treatment services centered on ketamine-based therapies. The core clinical offerings include Ketamine Infusions (IV administration for mental health and chronic pain), Ketamine-Assisted Psychotherapy (KAP with intramuscular ketamine combined with preparation and integration therapy), and SPRAVATO (FDA-approved esketamine nasal spray). Supporting services include Wellness IV infusions (Myers Mix, Immunity Boost, Revitalize), Longevity Medicine with NAD+ and peptide therapy, and Wellness Coaching. The organization also conducts psychedelic clinical research through partnerships with COMPASS Pathways (COMP360 psilocybin), atai/Beckley (VLS-01 DMT), and Cybin (psilocin studies). Additional offerings include group KAP retreats and at-home ketamine therapy via the Nue Life partnership.

Differentiator

Problem solved

Functional benefit

Products and services

• Ketamine Infusions Intravenous ketamine administration offered as 1-hour sessions for mental health ($500 self-pay; $250 with insurance) and 2-hour sessions for chronic pain ($850 self-pay), with precise dosing, rapid onset, consistent absorption, and real-time dose adjustments. 6-session and 3-session bundles available for private pay. For adults with treatment-resistant mental health conditions and chronic pain syndrome.
• Ketamine-Assisted Psychotherapy (KAP) Intramuscular ketamine combined with therapeutic preparation and integration sessions. Includes evaluation, preparation (1-3 sessions), medicine session with physician and therapist present, and integration (2-3 sessions). Available for individuals ($850 per session self-pay) and groups ($500 each; minimum 2 participants). For adults seeking ketamine-assisted psychotherapy with structured integration support.
• SPRAVATO (esketamine) FDA-approved esketamine nasal spray for treatment-resistant depression, typically covered by most insurance plans. Follows FDA-guided induction protocol of two treatments per week for four weeks. For adults with treatment-resistant depression.
• IV Therapy / Wellness Infusions Vitamin and mineral IV infusions including Myers Mix, Immunity Boost, and Revitalize formulations ($225 each), available as standalone wellness support or as a $150 add-on to ketamine infusions. NAD+ therapy also available for longevity. For adults seeking wellness and nutritional support.
• Longevity Medicine Anti-aging and longevity consultations including NAD+ IV therapy for cellular repair and energy production, peptide therapy, and personalized wellness consultations. Initial evaluation $500 (60 min); follow-up $250 per 30 minutes. For adults seeking longevity and anti-aging interventions.
• Peptide Therapy Specialized peptide-based treatments for various health and wellness goals offered as part of the longevity medicine program. For adults seeking peptide therapy for wellness, recovery, or anti-aging goals.
• Wellness Coaching Coaching services including free 20-minute consultations and structured packages: 3-session ($210, $70/session), 6-session ($390, $65/session), 9-session ($540, $60/session), and a specialized 5-session 'Whole Body Mental Health' package ($350, $70/session) with workbook. For adults seeking coaching support alongside ketamine therapy.
• Ketamine-Assisted Therapy Group Retreat Day-long group ketamine-assisted psychotherapy retreats held at Art of Counseling in St. Paul, MN, including a group preparation session, full KAP experience, and group integration circle. Priced at $600 per participant. Facilitated by Dr. Manoj Doss, Heather Matson LMFT ATR-BC ATCS, and Amie Summers LICSW SEP. For adults seeking community-based ketamine-assisted therapy.
• At-Home Sublingual Ketamine Therapy Partnered with Nue Life to offer at-home ketamine treatment using sublingual lozenges, including personalized psychedelic treatment, health coaching, integration sessions, and progress tracking. Expands access to ketamine therapy for patients in Minnesota and Wisconsin who prefer at-home treatment.
• COMP360 Psilocybin Clinical Trial (Phase III) Phase III clinical trial site services evaluating COMP360 synthetic psilocybin for treatment-resistant depression in partnership with COMPASS Pathways. IIT contributes participant screening, dosing supervision, safety assessments, and long-term follow-up. For adults aged 18-85 with Treatment-Resistant Depression meeting study eligibility.
• VLS-01 DMT Clinical Trial (Phase II) Phase II clinical trial site services evaluating VLS-01 buccal film (DMT) for treatment-resistant depression in partnership with atai Life Sciences and Beckley Psytech. Provides participant support, medical monitoring, and GCP-aligned research execution. Study evaluates safety, efficacy, and tolerability of the DMT-based formulation. Not actively recruiting at time of source.
• CYB003 Psilocin Clinical Trial (Phase III) Phase III clinical trial site services evaluating CYB003 psilocin for Major Depressive Disorder in partnership with Cybin (now Helus Pharma). Participants continue current antidepressant medication during the study. For adults with Major Depressive Disorder meeting study eligibility.

Quantifiable outcome

• Rapid relief often described as 'a reset' that helps patients reconnect with life, relationships, and themselves
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• atai Life Sciences / Beckley PsytechcoreStrategic or Co-development Partner · 16 December 2025atai Life Sciences and Beckley Psytech are pioneering short-duration psychedelic compounds, including VLS-01 (DMT). IIT serves as a clinical trial site for the VLS-01 DMT TRD study (VLS-01-203 trial), providing participant support, medical monitoring, and GCP-aligned research execution. The study evaluates safety, efficacy, and tolerability of a new DMT-based formulation.
• Cybin (now Helus Pharma)coreStrategic or Co-development Partner · 20 November 2025Cybin is an innovative biopharmaceutical company advancing next-generation psychedelic-derived treatments for mental health conditions. Their work focuses on precision science, improved delivery methods, and developing accessible, scalable therapeutic models. IIT was selected as a clinical trial site for Cybin's EMBRACE and EXTEND studies evaluating psilocin-based treatments for Major Depressive Disorder. Enrollment expected to begin February 2026.
• COMPASS PathwayscoreStrategic or Co-development PartnerCOMPASS Pathways leads the development of COMP360 psilocybin for Treatment-Resistant Depression. IIT is an approved clinical site for the COMP006 trial, contributing expertise in participant screening, dosing supervision, safety assessments, and long-term follow-up. This partnership enables IIT to offer Phase 3 psilocybin trials to patients in Minnesota.
• University of Wisconsin-Madison - Psychoactive Pharmaceutical Investigation (PPI) Master's ProgramsupportingStrategic or Co-development PartnerIIT is an official internship site for UW-Madison's PPI Master's Program, one of the nation's premier psychedelic science graduate programs. PPI students receive hands-on training in clinical trial operations, participant screening and eligibility workflows, research coordination, documentation and GCP-compliant data handling, and observing psychedelic-adjacent care models. Dr. Doss created this clinical research internship program.
• Nue LifesupportingTechnology or IntegrationIIT has partnered with Nue Life to offer at-home psychedelic treatment options. Nue Life provides personalized psychedelic treatment including health coaching, integration sessions, and progress tracking for sublingual ketamine therapy. This partnership expands access to at-home treatment options for patients in Minnesota and Wisconsin.
• Art of CounselingsupportingImplementation/ SI/ Consulting PartnerArt of Counseling in St. Paul, MN serves as the venue for IIT's group ketamine-assisted therapy day-long retreats. The retreat is facilitated by Dr. Manoj Doss (IIT), Heather Matson LMFT ATR-BC ATCS, and Amie Summers LICSW SEP (IIT).

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• COMPASS Pathways: COMPASS Pathways is developing COMP360 psilocybin for treatment-resistant depression and is currently an IIT clinical trial sponsor. Relevant as a sponsor-partner shaping IIT's research revenue and as the benchmark for the value of an FDA-approvable psychedelic therapy franchise.
• atai Life Sciences: atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic mental health therapies, including VLS-01 DMT, and is an IIT trial sponsor. Comparable as a sponsor and as the development-stage owner of compounds that drive IIT's clinical research revenue.
• Cybin: Cybin (now Helus Pharma) is developing psilocin-based therapies for major depressive disorder, including CYB003 (EMBRACE/EXTEND), and is an IIT clinical trial sponsor. Comparable as a sponsor driving IIT's research revenue stream and as a competitor for clinical site mindshare in psychedelic trials.

Direct peers

• Innerwell: Innerwell is a virtual ketamine-assisted psychotherapy platform offering at-home treatment with licensed therapists. Comparable as a psychedelic therapy provider targeting treatment-resistant depression and anxiety, competing for the same patient population through a telehealth model.
• Nushama: Nushama is a psychedelic medicine clinic offering ketamine-assisted therapy and integration services in New York. Directly comparable to IIT as a vertically integrated outpatient psychedelic therapy provider combining physician oversight, integration coaching, and clinical research partnerships.
• Klarisana: Klarisana is a ketamine therapy clinic network headquartered in Texas offering IV ketamine infusions for mental health and chronic pain. Directly comparable to IIT as a regional outpatient ketamine clinic with physician oversight, similar self-pay pricing, and chronic-pain plus mental-health indications.
• Nue Life: Nue Life provides at-home psychedelic therapy with health coaching, integration, and progress tracking, and is an existing IIT partner. Comparable as a psychedelic therapy provider with overlapping clinical model and overlapping patient demographic; functions as both a partner and a competing channel for ketamine demand.
• Field Trip Health: Field Trip Health operated ketamine-assisted psychotherapy clinics across North America before restructuring in 2023. Closest historical analog to IIT's clinic-plus-research model; relevant as a benchmark for clinic economics and as a cautionary comparable on capital-intensive multi-site expansion.
• Mindbloom: Mindbloom is the largest at-home ketamine therapy provider in the US, offering sublingual ketamine with remote clinician oversight. Comparable as a psychedelic therapy operator targeting treatment-resistant depression; competes for the same patient cohort via a telehealth-led, lower-cost delivery model.
• Actify Neurotherapies: Actify Neurotherapies (formerly CNS Healthcare) operates a national network of outpatient clinics offering ketamine infusion therapy for depression, PTSD, and chronic pain. Comparable to IIT as a multi-state outpatient ketamine provider with similar indications and physician-supervised delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/psychedelictherapymn
• LinkedInlinkedin.com/company/institute-for-integrative-therapies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute for Integrative Therapies